47 results
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
27 Nov 23
Other Events
7:03am
at the upcoming American Epilepsy Society meeting in December.”
About the Phase 2 X-NOVA Clinical Trial in MDD
The Phase 2 proof-of-concept X-NOVA clinical
424B5
XENE
Xenon Pharmaceuticals Inc
6 Oct 21
Prospectus supplement for primary offering
5:05pm
of the American Epilepsy Society in December 2020. The lead investigator has expanded the study to include an additional site, which is currently screening
424B5
XENE
Xenon Pharmaceuticals Inc
4 Oct 21
Prospectus supplement for primary offering
5:27pm
Society in December 2020. The lead investigator has expanded the study to include an additional site, which is currently screening patients, and is also
8-K
EX-99.1
6irup
11 Aug 21
Xenon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:16pm
8-K
EX-99.1
4ymw4spixgv3zo3
11 May 21
Xenon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:17pm
424B5
65arr35p5h 12zp6
9 Mar 21
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
22q0ozks4m4
1 Mar 21
Xenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate Update
4:04pm
8-K
EX-10.3
6nujr
14 Jan 21
Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for Third Quarter of 2021
8:05am
8-K
EX-10.2
kgeko
14 Jan 21
Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for Third Quarter of 2021
8:05am
8-K
EX-99.1
4ly03ycqtv5r3npd
14 Jan 21
Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for Third Quarter of 2021
8:05am
8-K
EX-10.4
6l0v504n
14 Jan 21
Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for Third Quarter of 2021
8:05am
8-K
EX-99.1
4q6zmv ae
5 Nov 20
Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
4:11pm